BIOV — Biovaxys Technology Balance Sheet
0.000.00%
Last trade - 00:00- CA$7.34m
- CA$7.47m
Annual balance sheet for Biovaxys Technology, fiscal year end - October 31st, CAD millions except per share, conversion factor applied.
2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 October 31st | 2024 October 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 2.42 | 0.593 | 0.142 | 0.001 | 0.212 |
| Net Total Receivables | 0.048 | 0.133 | 0.212 | 0.088 | 0.436 |
| Prepaid Expenses | |||||
| Total Current Assets | 3.06 | 0.874 | 0.715 | 0.113 | 1.3 |
| Net Property, Plant And Equipment | 0 | — | — | — | — |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 10.5 | 8.5 | 0.866 | 0.113 | 1.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.9 | 0.327 | 1.64 | 3.49 | 3.22 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.9 | 0.327 | 1.64 | 3.49 | 3.22 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 9.56 | 8.18 | -0.774 | -3.37 | -1.92 |
| Total Liabilities & Shareholders' Equity | 10.5 | 8.5 | 0.866 | 0.113 | 1.3 |
| Total Common Shares Outstanding |